When scientific evidence gets in the way of political goals, the Trump administration appears to be following a pattern of rejecting the data, writes Joshua Sharfstein from the Johns Hopkins Bloomberg School of Public Health at JAMA Forum.
Registering provides access to this and other free content.
Already have an account?Login Now.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.